TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
Tumor protein p53 (TP53) is a tumor suppressor gene and TP53 mutations are associated with poor prognosis in non-small cell lung cancer. However, the in-depth classification of TP53 and its relationship with treatment response and prognosis in epidermal growth factor receptor (EGFR)-mutant tumors tr...
Main Authors: | Ruofei Yu, Hua Bai, Tangai Li, Bingyu Gao, Jiefei Han, Geyun Chang, Pei Zhang, Kailun Fei, Xiran He, Jie Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523321001558 |
Similar Items
-
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
by: Hao Sun, et al.
Published: (2020-10-01) -
Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
by: Cheyennedra C. Bieg‐Bourne, et al.
Published: (2020-06-01) -
Analysis of TP53 Codon 72 Polymorphism in Mucinous and Non-Mucinous Colorectal Adenocarcinoma in Isfahan, Iran
by: Mehdi Nikbahkt Dastjerdi
Published: (2010-03-01) -
Expressions of TP53, PDGF and EGFR in Primary Astrocytomas and Their Correlation with Clinicopathological Features and Prognosis
by: SUN Xiaoling, et al.
Published: (2021-02-01) -
The TP53 fertility network
by: Diego d'Avila Paskulin, et al.
Published: (2012-01-01)